Double-sided Hansen Pharmaceuticals: With Gold Sales and Innovative Players

Pharmaceutical Network on May 14th, Hong Kong's largest stock market value of the pharmaceutical stocks Hensen Pharmaceuticals was lifted a cornerThe bribery case of Lei Lipei, the former director of the anesthesiology department of Lishui City Hospital in Zhejiang Province, brought the ills of medical bribes and gold sales to the public againUnder the continued media attention, pulling out the radish to bring out the mud, a number of pharmaceutical companies bribery scandals were salvaged, including henson pharmaceutical companies such as the star companyHenson Pharmaceuticals, which goes public in June 2019, is the wife of Sun Hong, the mainland's largest pharmaceutical company by market capitalisation, and Hengrui PharmaceuticalsOn May 10, Hansen Pharmaceuticals just launched its fourth independent innovation drug, focusing on creating innovative people in the domestic pharmaceutical market, which is dominated by generic drugsThe bribery wave continued to fester, and Hansen Pharmaceuticals was brought to the publicAccording to reports, Hensen Pharmaceuticals from 2010 to 2017 has repeatedly paid bribes to hospital-related officials,centralized procurement service centers, and expanded the company's drug sales through gold salesreporters in the judgment paper online to see, according to the defendant Salt City Dafeng People's Hospital Pharmacy Department of the former director of Jiang Xueqiu's confession, the relevant evidence confirmed that it received Jiangsu Hengte Pharmaceutical Sales Co., Ltd(a subsidiary of Hansen Pharmaceuticals) a bribe sent 10,000 yuanWitness Gao is the manager of Jiangsu Hengte Pharmaceutical Sales Co., Ltd., responsible for the sale of hensen Pharmaceutical selling drugsOne day in the second half of 2017, he sent 10,000 yuan to Jiang Xueqiu's office of the People's Hospital, thanking Jiang Xueqiu for his company's business concern, the aim is to hope that Jiang Xueqiu in the formulation of drug procurement plans and deployment of care, as well as the 2017 provincial and municipal drugcatalog published, please Jiang Xueqiu care about the purchase of its company's drugs, before the 2010 Mid-Autumn Festival, 2011-2013 before the Spring Festival, before the Mid-Autumn Festival, Hu Fengping, the former director of Anhui Province's Pharmaceutical Central Procurement Service Center, received seven times in the office of Jiangsu Hent Pharmaceutical Sales Co., Ltdemployees a total value of 14,000 yuan shopping card, for the staff to provide information on bidding, for the company's production of drugs to participate in the bidding to helpwith gold sales has been a persistent problem in the industryThe sale of gold, also known as the sale of gold, was originally used in the hospital as the main point-of-sale of prescription drugs, that is, to doctors with prescription rights for gold promotion, the use of the authority of the doctor and the decision to use the drug for product sales According to the information, in April 2018, Novartis was reported by real name with gold sales, in May 2019, Sendai Pharmaceuticals was caught in a bribery scandal, and in August 2019, Mercado was reported to be the hospital illegal drug belt gold sales market competition continues to emerge, pharmaceutical companies through the doctor rebate to increase product sales, ease the pressure of competition, doctors eat rebate phenomenon repeatedly banned As one person close to the pharmaceutical representative put it, "The pharmaceutical industry is like this, and at home and abroad will be a little bit of a bit of a "gold sale") Quite simply, two drugs with the same effect, as a doctor, one of the drug companies to their own special 'good', replaced by you, who will you prescribe the medicine? "
for the company repeatedly caught in the bribery wave and other issues, the reporter interviewed the relevant person in charge of Hesen Pharmaceuticals, as of the draft, did not receive a reply At present, the domestic pharmaceutical market is still generic-led, similar products who have doctor resources who can make money "The market has more than one drug of the same effect, pharmaceutical companies through the sale of gold to expand drug sales, improve performance In contrast, the pharmaceutical companies in the sales of the investment is also huge The above-mentioned people told reporters According to its disclosure, the cost of selling with gold is mostly hidden in travel expenses and academic promotion fees, direct public payments to individuals in recent years, Hansen Pharmaceuticals has maintained a good development, revenue growth year by year However, high sales costs have also been criticized In 2016-2019, Henson Pharmaceuticals achieved revenue of RMB5,433 million, RMB6.186 billion, RMB7.722 billion and RMB8.683 billion, respectively, according to financial reports During the same period, the Company's sales and distribution expenditure was RMB 2,378 million, RMB 2,704 million, RMB3.209 billion and RMB3.266 billion, respectively, and the revenue share remained at about 40% The cost of sales at Henson Pharmaceuticals includes material costs, employee costs, depreciation, and other expenses Henson Pharmaceuticals' financial results do not disclose the specific proportion of cost of sales such as material costs and employee costs However, sales people are highly important by Hansen Pharmaceuticals Hansen Pharmaceuticals has said that successful sales and marketing are critical to the company's increased market penetration of listed products, expanding and other medical facilities, and that failure to effectively promote or maintain a competent sales force could adversely affect product sales and business prospects According to the prospectus, by the end of 2018, Hansen Pharmaceuticals will promote and sell its products through an internal sales team of about 4,500 sales professionals In its prospectus, Hansen Pharmaceuticals said the company promotes awareness and awareness of the clinical benefits of the company's products and enhances product visibility through patient-centered, clinically data-oriented academic outreach activities The transition to innovation is a goal set by Henson Pharmaceuticals, which plans to launch 15 high-growth-focused drugs (including 4 1.1 innovative drugs and 8 potential first-in-the-top drugs) by 2019-2020 On May 10, Henson Pharmaceuticals' methamphetamine tablets, which are used to treat non-small cell lung cancer, went on the market With the launch of the metasuldonic amatinib tablet, The four 1.1-year-old innovative drugs from Henson Pharmaceuticals will be on the market for 2019-2020 have been completed For now, however, Hansen Pharmaceuticals' main source of revenue remains generics Mylinda (Sodium nitrate hydrochloride injection) is the latest generation of nitrite antibiotic 1.1 innovative drug developed independently by Henson Pharmaceuticals, which was approved for sale in China by the State Drug Administration in 2014 According to the prospectus, from 2017 to 2018, Mylinda's sales accounted for 0.2% and 0.9% of Henson Pharmaceuticals' total revenue, or about 124 million yuan and 695 million yuan, respectively According to Frost and Sullivan, sales of nitromymin drugs in China were 5.8 billion yuan in 2017, with mylinda's market share of about 2.1 percent 2019 results have not yet disclosed the revenue figures for Hamen Pharmaceuticals' first independent lying drug, Mylinda In terms of categories, mylinda's anti-infective products category achieved revenue of RMB1,829 million, accounting for about 21.1% of the company's total revenue The category also includes the first generic drugs Zetan, Hengjie and Hengsen 2019 is the year of innovation at Henson Pharmaceuticals, which welcomed two 1.1-type innovative drugs, respectively, Foraday and Haussen Similarly, Henson Pharmaceuticals did not disclose the specific revenue figures for the two drugs in its 2019 earnings report, and it was not clear how much it would be in terms of categories, The company's total revenue was RMB1,153 million, accounting for about 13.3% of the company's total revenue, in the digestive, diabetes and cardiovascular sectors to which the company belongs Haussen's anti-tumor products category achieved revenue of 3.53 billion yuan, accounting for about 40.6% of the company's total revenue However, in addition to Hausen," the anti-tumor productcategory includes Pryor, Zephyr, Weiwei, Yumei, Yantai, and Tanner Public information shows that Pryor, Zefei are sales of more than 1 billion yuan of an industry source told reporters that the application of Mylinda and Haussen Fu is small, and Fu Mei to do doctor patient education, slowly climbthe hill to release economist Song Qinghui believes that the proportion of sales costs far exceeds the proportion of research and development costs, sales costs to a certain extent will erode the company's innovation investment, so that the company's innovation transformation strategy extended According to the data, in 2016-2019, Henson Pharmaceuticals' sales and distribution expenses accounted for 43.8%, 43.7%, 41.6% and 37.6% of total revenue, respectively Research and development expenditure was RMB403 million, RMB 576 million, RMB881 million and RMB1,121 million, respectively, accounting for 7.4%, 9.3%, 11.4% and 12.9% of total revenue.